[Similarities between amyotrophic lateral sclerosis and frontotemporal dementia].

Frontotemporal dementia (FTD) is characterized by degeneration of the frontal and temporal lobes. Classic symptoms include behavioural alterations and executive dysfunction. Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease of the first and second motoneurones, as well as of cortical neurons, presenting with weakness and wasting of the limb, respiratory and bulbar muscles.

Case Series of Acute Peripheral Neuropathies in Individuals Who Received COVID-19 Vaccination.

: Vaccination has been critical to managing the COVID-19 pandemic. Autoimmunity of the nervous system, especially among a select set of high-risk groups, can be triggered or enhanced by the contents of vaccines. Here, we report a case series of acute peripheral neuropathies following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Relaxation-weighted Na magnetic resonance imaging maps regional patterns of abnormal sodium concentrations in amyotrophic lateral sclerosis.

Objectives: Multiparametric magnetic resonance imaging (MRI) is established as a technical instrument for the characterisation of patients with amyotrophic lateral sclerosis (ALS). The contribution of relaxation-weighted sodium (NaR) MRI remains to be defined. The aim of this study is to apply NaR MRI to investigate brain sodium homeostasis and map potential alterations in patients with ALS as compared with healthy controls.

Are nerve conduction studies altered in functional neurological disorders?

Background: Functional neurological disorders represent conditions without a readily identifiable origin or laboratory-supported diagnostic. We report a case of functional neurological disorder, presenting with muscle weakness with alterations in F-waves on the affected side.

Case Report: A retrospective case review of a patient seen in clinic.

[Treating hereditary neuropathies : a dream come true?].

Hereditary neuropathies have been the subject of recent major therapeutic advances. Treatments based on antisense oligonucleotides (ASO) and small interfering RNA (siRNA) have been developed and are now commercially available to treat hereditary transthyretin amyloidosis (hTTR) and porphyria. More recently, a CRISPR-Cas9 genomic editing treatment targeting the TTR gene has been developed and is being tested in patients with hTTR.